ArticlePloS one2015
Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Endocervical crypt involvement by high-grade cervical intraepithelial neoplasia and its association with high-grade histopathological recurrence after cervical excision in women with negative excision margins: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2024Pooled it
- Informative HPV testing after conization and its impact on time-varying estimates: a GAMM-based cohort study.Frontiers in public health · 2026Article
- Cervical conization and high risk - HPV status changes in relation to menopause: a retrospective longitudinal study based on generalized additive mixed models.BMC infectious diseases · 2025Article
- Risk factors of recurrent cervical intraepithelial neoplasm 2/3 after primary excisional conization/LEEP treatments: A follow-up nationwide cohort study.European journal of obstetrics & gynecology and reproductive biology: X · 2025Article
- Article
- IGF2BP3-mediated regulation ofAmerican journal of cancer research · 2023Article
- Review
- Risk factors associated with HPV persistence after conization in high-grade squamous intraepithelial lesion.Archives of gynecology and obstetrics · 2021Review
- Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women.Journal of gynecologic oncology · 2020Article
- Prognostic significance of TPX2 and NIBP in esophageal cancer.Oncology letters · 2019Article
- Key Molecular Events in Cervical Cancer Development.Medicina (Kaunas, Lithuania) · 2019Review
- The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.Frontiers in oncology · 2019Review
- PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors.American journal of clinical and experimental urology · 2019Article
- Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.Journal of gynecologic oncology · 2018Article
- Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis.International journal of biological sciences · 2018Article
- Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.Diagnostic pathology · 2017Article
- Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo determine the clinicopathologic and immunohistochemical predictors of the persistence/recurrence of cervical intraepithelial neoplasia (CIN) after cervical conization.
methodsMedical records of 502 patients who received cervical conization treatment of CIN between 2005 and 2012 were reviewed. The clinicopathologic parameters were analyzed using Cox hazard regression. Fifty patients with CIN persistence/recurrence were matched to 50 cases without CIN persistence/recurrence. These 100 cervical specimens were assessed for expression of insulin-like growth factor II messenger RNA (mRNA)-binding protein 3 (IMP3), targeting protein for xenopus kinesin-like protein 2 (TPX2), and programmed cell death-1 ligand-1 (PD-L1) using immunohistochemical staining.
resultsMultivariate analysis found that the independent predictors of CIN persistence/recurrence were positive surgical margin (hazard ratio 5.777, 95% confidence interval 2.334-14.301, p < 0.001) and human papilloma virus persistence for 6 months (hazard ratio 20.685, 95% confidence interval 7.350-57.657, p < 0.001). Co-expression of TPX2 and PD-L1 was significantly higher in CIN persistence/recurrence group than the group without CIN persistence/recurrence (p = 0.013). The depth of glandular involvement (GI) was less than 3mm in about 86.8% (59/68) CIN2-3 lesions, However, No statistically significant associations between GI and persistence/recurrence were observed (P = 0.58).
conclusionPositive surgical margin, HPV persistence, and expression of both TPX2 and PD-L1 are associated with persistence/recurrence of cervical intraepithelial neoplasia after cervical conization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.